Home/Pipeline/JOTROL™

JOTROL™

Alzheimer's Disease

ClinicalActive

Key Facts

Indication
Alzheimer's Disease
Phase
Clinical
Status
Active
Company

About Jupiter Neurosciences

Jupiter Neurosciences is a private, clinical-stage company founded in 2019, developing novel oral therapies targeting neuroinflammation. Its lead platform, JOTROL™, is a patented micellar formulation of resveratrol designed to overcome poor bioavailability and enable therapeutic dosing for central nervous system disorders. The company's strategy involves a dual-path pipeline, with a long-term focus on Alzheimer's disease and parallel development in rare, orphan neurological indications. Jupiter appears to be pre-revenue and is likely funded by private investment as it advances its programs.

View full company profile

About Jupiter Neurosciences

Jupiter Neurosciences is a private, clinical-stage company founded in 2019, developing novel oral therapies targeting neuroinflammation. Its lead platform, JOTROL™, is a patented micellar formulation of resveratrol designed to overcome poor bioavailability and enable therapeutic dosing for central nervous system disorders. The company's strategy involves a dual-path pipeline, with a long-term focus on Alzheimer's disease and parallel development in rare, orphan neurological indications. Jupiter appears to be pre-revenue and is likely funded by private investment as it advances its programs.

View full company profile

Other Alzheimer's Disease Drugs

DrugCompanyPhase
NUZ-001Neurizon TherapeuticsPreclinical
ALZN002Alzamend NeuroPreclinical
P021Phanes BiotechPreclinical
PB43DPhanes BiotechPreclinical
UB-311VaxxinityPhase 2
LecanemabBioArcticLaunched
BAN2401BioArcticPreclinical
Undisclosed Programsjohnson-and-johnson-innovative-medicinePipeline
MK-6240 (florquinitau)Lantheus Medical ImagingRegulatory Filing
NAV-4694 (flutafuranol)Lantheus Medical ImagingPhase 3
LNTH-2620/PI-2620Lantheus Medical ImagingPhase 3
itMSCsStemedica Cell TechnologiesClinical Development